Author:
Capone Stefania,Raggioli Angelo,Gentile Michela,Battella Simone,Lahm Armin,Sommella Andrea,Contino Alessandra Maria,Urbanowicz Richard A.,Scala Romina,Barra Federica,Leuzzi Adriano,Lilli Eleonora,Miselli Giuseppina,Noto Alessia,Ferraiuolo Maria,Talotta Francesco,Tsoleridis Theocharis,Castilletti Concetta,Matusali Giulia,Colavita Francesca,Lapa Daniele,Meschi Silvia,Capobianchi Maria,Soriani Marco,Folgori Antonella,Ball Jonathan K.,Colloca Stefano,Vitelli Alessandra
Abstract
ABSTRACTThe COVID-19 pandemic caused by the emergent SARS-CoV-2 coronavirus threatens global public health and there is an urgent need to develop safe and effective vaccines. Here we report the generation and the preclinical evaluation of a novel replication-defective gorilla adenovirus-vectored vaccine encoding the pre-fusion stabilized Spike (S) protein of SARS-CoV2. We show that our vaccine candidate, GRAd- COV2, is highly immunogenic both in mice and macaques, eliciting both functional antibodies which neutralize SARS-CoV-2 infection and block Spike protein binding to the ACE2 receptor, and a robust, Th1- dominated cellular response in the periphery and in the lung. We show here that the pre-fusion stabilized Spike antigen is superior to the wild type in inducing ACE2-interfering, SARS-CoV2 neutralizing antibodies. To face the unprecedented need for vaccine manufacturing at massive scale, different GRAd genome deletions were compared to select the vector backbone showing the highest productivity in stirred tank bioreactors. This preliminary dataset identified GRAd-COV2 as a potential COVID-19 vaccine candidate, supporting the translation of GRAd-COV2 vaccine in a currently ongoing Phase I clinical trial (NCT04528641).
Publisher
Cold Spring Harbor Laboratory
Cited by
6 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献